144 related articles for article (PubMed ID: 37216403)
41. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
42. Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: Systematic Review and Meta-Analysis.
Huang W; de la Iglesia-García D; Baston-Rey I; Calviño-Suarez C; Lariño-Noia J; Iglesias-Garcia J; Shi N; Zhang X; Cai W; Deng L; Moore D; Singh VK; Xia Q; Windsor JA; Domínguez-Muñoz JE; Sutton R
Dig Dis Sci; 2019 Jul; 64(7):1985-2005. PubMed ID: 31161524
[TBL] [Abstract][Full Text] [Related]
43. [Latest advances in chronic pancreatitis].
Domínguez Muñoz JE
Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():86-90. PubMed ID: 26520201
[TBL] [Abstract][Full Text] [Related]
44. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
45. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer.
Roeyen G; Berrevoet F; Borbath I; Geboes K; Peeters M; Topal B; Van Cutsem E; Van Laethem JL
ESMO Open; 2022 Feb; 7(1):100386. PubMed ID: 35124465
[TBL] [Abstract][Full Text] [Related]
46. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
47. Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report.
Verhaert M; Mebis J; Aspeslagh S; von Kemp B
Eur Heart J Case Rep; 2023 Mar; 7(3):ytad112. PubMed ID: 36937234
[TBL] [Abstract][Full Text] [Related]
48. Case report: Induction and maintenance of steroid-free remission with vedolizumab in a case of steroid-dependent autoimmune pancreatitis.
Griebel P; Tran F; Luehring J; Schreiber S
Front Immunol; 2023; 14():1201363. PubMed ID: 37404824
[TBL] [Abstract][Full Text] [Related]
49. Rituximab in steroid-refractory immune-related pancreatitis: a case report.
Santoro A; Masini S; Cavina R; Tronconi MC; De Vincenzo F
Front Oncol; 2023; 13():1205720. PubMed ID: 37588091
[TBL] [Abstract][Full Text] [Related]
50. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
[TBL] [Abstract][Full Text] [Related]
51. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
52. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent.
Forsmark CE; Tang G; Xu H; Tuft M; Hughes SJ; Yadav D
Aliment Pharmacol Ther; 2020 May; 51(10):958-967. PubMed ID: 32249970
[TBL] [Abstract][Full Text] [Related]
53. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
[TBL] [Abstract][Full Text] [Related]
54. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
55. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
[TBL] [Abstract][Full Text] [Related]
56. Subclinical exocrine pancreatic insufficiency in dogs.
Wiberg ME; Westermarck E
J Am Vet Med Assoc; 2002 Apr; 220(8):1183-7. PubMed ID: 11990965
[TBL] [Abstract][Full Text] [Related]
57. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
58. Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency.
Barresi L; Tacelli M; Crinò SF; Attili F; Petrone MC; De Nucci G; Carrara S; Manfredi G; Capurso G; De Angelis CG; Crocellà L; Fantin A; Dore MF; Garribba AT; Tarantino I; De Pretis N; Pagliari D; Rossi G; Manes G; Preatoni P; Barbuscio I; Tuzzolino F; Traina M; Frulloni L; Costamagna G; Arcidiacono PG; Buscarini E; Pezzilli R;
United European Gastroenterol J; 2020 Jul; 8(6):705-715. PubMed ID: 32397913
[TBL] [Abstract][Full Text] [Related]
59. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
60. Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging.
Thomas AS; Abreo M; Sayed SA; Sireesha Yedururi YW; Chari ST
Gastroenterology; 2023 Jan; 164(1):154-155. PubMed ID: 36220459
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
